Sickle cell disease trials recruiting in Virginia

All Sickle cell disease trials nationally

Cities in Virginia

Recruiting trials in Virginia

• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Virginia: Richmond
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax, Richmond
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Virginia: Fairfax, Norfolk, Richmond
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
  NCT04398628 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Virginia: Norfolk
• Early Screening and Treatment of Heart Complication in Sickle Cell Disease
  NCT07023666 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax, Falls Church
• Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
  NCT06374238 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 30 Years · Sex: All (male and female) · Virginia: Richmond
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
  NCT07224360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Richmond
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Virginia: Richmond
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female) · Virginia: Richmond